Preparation Of Recombinant Protein And Gene Drugs Based On Survivin And Their Pro-apoptic Effect On Cancer Cells In Vivo And In Vitro

Survivin, a new member of IAP family, was found in human genbank by Aitieric. DC from Yale University in 1997. It was identified in most cancerous tissues from human being; however, it was not detected from adult normal tissues. It was proven that survivin plays a role in regulating cell cycles and inhibiting cell apoptosis by restraining caspases-3 and -7 directly and binding mitochondrial protein. Recent researches indicated that expression of survivin was correlated with tumor grade, recurrence risk, and patients' survival. Hence, survivin has been thought as a significant marker for cancer therapy and paid more attention as the target of anticancer due to its specificity of expression in cancer cell. Since survivin was located in cytoplasm, research and development of new anticancer drugs targeting survivin had mainly been focused on gene level, for example antisense oligonucleotides, dominant negative mutants, ribozymes and small interfering RNAs to down-regulate survivin expression/function, increase the apoptotic rate, reduce tumor-growth potential and sensitize tumor cells to chemotherapeutic drugs. Some drugs for gene therapy introduced by virus transfection have made some progresses in cancer treatment recently, but the safety of gene therapy remained misgivings to patients.In the research, cDNAs of survivin and three splice variants were cloned by...